These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 27262432)

  • 1. A State Transition Model for Health Outcomes Associated with Vorapaxar Treatment as an Add-on to Standard Care Antiplatelet Therapy in the Prevention of Thrombotic Events for Patients with a Recent Myocardial Infarction.
    Whalen JD; Davies G; Du M; Oguz M; Bash LD; Ozer-Stillman I
    Am J Cardiovasc Drugs; 2016 Aug; 16(4):285-295. PubMed ID: 27262432
    [TBL] [Abstract][Full Text] [Related]  

  • 2. State transition model: vorapaxar added to standard antiplatelet therapy to prevent thrombosis post myocardial infarction or peripheral artery disease.
    Du M; Chase M; Oguz M; Davies G
    Curr Med Res Opin; 2017 Sep; 33(9):1535-1543. PubMed ID: 28277861
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of vorapaxar as approved for clinical use in the United States.
    Magnani G; Bonaca MP; Braunwald E; Dalby AJ; Fox KA; Murphy SA; Nicolau JC; Oude Ophuis T; Scirica BM; Spinar J; Theroux P; Morrow DA
    J Am Heart Assoc; 2015 Mar; 4(3):e001505. PubMed ID: 25792124
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Vorapaxar: A Protease-Activated Receptor Antagonist for the Prevention of Thrombotic Events.
    Lam S; Tran T
    Cardiol Rev; 2015; 23(5):261-7. PubMed ID: 25923910
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Vorapaxar: a review of its use in the long-term secondary prevention of atherothrombotic events.
    Frampton JE
    Drugs; 2015 May; 75(7):797-808. PubMed ID: 25895464
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Vorapaxar for secondary prevention of thrombotic events for patients with previous myocardial infarction: a prespecified subgroup analysis of the TRA 2°P-TIMI 50 trial.
    Scirica BM; Bonaca MP; Braunwald E; De Ferrari GM; Isaza D; Lewis BS; Mehrhof F; Merlini PA; Murphy SA; Sabatine MS; Tendera M; Van de Werf F; Wilcox R; Morrow DA;
    Lancet; 2012 Oct; 380(9850):1317-24. PubMed ID: 22932716
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Vorapaxar for reduction of thrombotic cardiovascular events in myocardial infarction and peripheral artery disease.
    Arif SA; D'Souza J; Gil M; Gim S
    Am J Health Syst Pharm; 2015 Oct; 72(19):1615-22. PubMed ID: 26386102
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Vorapaxar in the secondary prevention of atherothrombosis.
    Tantry US; Liu F; Chen G; Gurbel PA
    Expert Rev Cardiovasc Ther; 2015 Dec; 13(12):1293-305. PubMed ID: 26559689
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Vorapaxar in patients with diabetes mellitus and previous myocardial infarction: findings from the thrombin receptor antagonist in secondary prevention of atherothrombotic ischemic events-TIMI 50 trial.
    Cavender MA; Scirica BM; Bonaca MP; Angiolillo DJ; Dalby AJ; Dellborg M; Morais J; Murphy SA; Ophuis TO; Tendera M; Braunwald E; Morrow DA
    Circulation; 2015 Mar; 131(12):1047-53. PubMed ID: 25681464
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Atherothrombotic Risk Stratification and the Efficacy and Safety of Vorapaxar in Patients With Stable Ischemic Heart Disease and Previous Myocardial Infarction.
    Bohula EA; Bonaca MP; Braunwald E; Aylward PE; Corbalan R; De Ferrari GM; He P; Lewis BS; Merlini PA; Murphy SA; Sabatine MS; Scirica BM; Morrow DA
    Circulation; 2016 Jul; 134(4):304-13. PubMed ID: 27440003
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Improving Outcomes in Cardiovascular Diseases: A Review on Vorapaxar.
    Chaudhary R; Mohananey A; Sharma SP; Singh S; Singh A; Kondur A
    Cardiol Rev; 2022 Sep-Oct 01; 30(5):241-246. PubMed ID: 33758122
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Vorapaxar in patients with coronary artery bypass grafting: Findings from the TRA 2°P-TIMI 50 trial.
    Kosova EC; Bonaca MP; Dellborg M; He P; Morais J; Oude Ophuis T; Scirica BM; Tendera M; Theroux P; Braunwald E; Morrow DA
    Eur Heart J Acute Cardiovasc Care; 2017 Mar; 6(2):164-172. PubMed ID: 27075924
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Vorapaxar in the secondary prevention of atherothrombotic events.
    Morrow DA; Braunwald E; Bonaca MP; Ameriso SF; Dalby AJ; Fish MP; Fox KA; Lipka LJ; Liu X; Nicolau JC; Ophuis AJ; Paolasso E; Scirica BM; Spinar J; Theroux P; Wiviott SD; Strony J; Murphy SA;
    N Engl J Med; 2012 Apr; 366(15):1404-13. PubMed ID: 22443427
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adjunctive therapies to reduce thrombotic events in patients with a history of myocardial infarction: role of vorapaxar.
    Farag M; Patel H; Gorog DA
    Drug Des Devel Ther; 2015; 9():3801-9. PubMed ID: 26229441
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Vorapaxar in atherosclerotic disease management.
    Cheng JW; Colucci V; Howard PA; Nappi JM; Spinler SA
    Ann Pharmacother; 2015 May; 49(5):599-606. PubMed ID: 25680760
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of more potent antiplatelet therapy with vorapaxar in patients with impaired renal function.
    Correa S; Bonaca MP; Scirica BM; Murphy SA; Goodrich EL; Morrow DA; O'Donoghue ML
    J Thromb Thrombolysis; 2019 Apr; 47(3):353-360. PubMed ID: 30511258
    [TBL] [Abstract][Full Text] [Related]  

  • 17. New ischemic stroke and outcomes with vorapaxar versus placebo: results from the TRA 2 °P-TIMI 50 trial.
    Bonaca MP; Scirica BM; Braunwald E; Wiviott SD; Goto S; Nilsen DW; Bonarjee V; Murphy SA; Morrow DA
    J Am Coll Cardiol; 2014 Dec; 64(22):2318-26. PubMed ID: 25465417
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and Safety of Vorapaxar With and Without a Thienopyridine for Secondary Prevention in Patients With Previous Myocardial Infarction and No History of Stroke or Transient Ischemic Attack: Results from TRA 2°P-TIMI 50.
    Bohula EA; Aylward PE; Bonaca MP; Corbalan RL; Kiss RG; Murphy SA; Scirica BM; White H; Braunwald E; Morrow DA
    Circulation; 2015 Nov; 132(20):1871-9. PubMed ID: 26338971
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Vorapaxar with or without clopidogrel after non-ST-segment elevation acute coronary syndromes: results from the thrombin receptor antagonist for clinical event reduction in acute coronary syndrome trial.
    Tricoci P; Lokhnygina Y; Huang Z; Van de Werf F; Cornel JH; Chen E; Wallentin L; Held C; Aylward PE; Moliterno DJ; Jennings LK; White HD; Armstrong PW; Harrington RA; Strony J; Mahaffey KW
    Am Heart J; 2014 Dec; 168(6):869-77.e1. PubMed ID: 25458650
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Vorapaxar monotherapy for secondary stroke prevention: A call for randomized trial.
    Serebruany VL; Kim MH; Hanley DF
    Int J Stroke; 2016 Aug; 11(6):614-7. PubMed ID: 26860124
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.